A group of investors from China recently participated in the funding round for US-based biopharmaceutical firm Sirnaomics, media reports said. The firm raised around $105 million in its Series D funding round.
The funding round for Sirnaomics was co-led by existing Chinese investor Rotating Boulder Fund, a Shenzhen-based equity investment firm, vaccines developer Walvax Biotechnology and private equity fund manager Sunshine Riverhead Capital.
Chinese healthcare-focused VC firm Sangel Capital, Longmen Capital, HongTao Capital, and Alpha Win Capital also participated in the Series D round. Meanwhile Chinese Renaissance and Huatai Financial Holdings served as the financial advisors, according to reports.
Patrick Lu, group founder, president and CEO at Siranomics, in a statement, “The syndicate of investors will not only strengthen our financial foundation, but also bring tremendous experience and expertise to Sirnaomics as it enters the next phase of growth and prepares for an initial public offering in near future.”
Last month, American multinational pharmaceutical company Pfizer has agreed to buy a 9.9 percent stake in China-based Cstone Pharmaceuticals. Pfizer agreed to buy 115.93 million new shares of CStone at HK$13.37 apiece, representing a 43.8 percent premium over the closing price of HK$9.30.
CStone said in a security exchange filing that it will use the proceeds from the share sale to fund development activities and strategic collaboration.
It was reported that the transaction has received the necessary internal approvals of both companies. Closing is not subject to approval by CStone’s shareholders. While Goldman Sachs is acting as financial advisor to CStone, Cooley LLP served as legal advisor. Clifford Chance LLP served as Pfizer’s legal advisor.